Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2006-11-30
This phase I/II trial studies the side effects and best dose of vaccine therapy when given
with or without cyclophosphamide and to see how well they work in treating patients with
multiple myeloma that has come back (recurrent) or has not responded to previous treatment
(refractory). Vaccines made from a gene-modified virus may help the body build an effective
immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy
together with cyclophosphamide may be a better treatment for multiple myeloma.
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Completed
Mayo Clinic
Phase 1/Phase 2
2006-11-30
This phase I/II trial studies the side effects and best dose of vaccine therapy when given
with or without cyclophosphamide and to see how well they work in treating patients with
multiple myeloma that has come back (recurrent) or has not responded to previous treatment
(refractory). Vaccines made from a gene-modified virus may help the body build an effective
immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy
together with cyclophosphamide may be a better treatment for multiple myeloma.
A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years
Completed
National Institute for Health Research, United Kingdom
Phase 4
2010-03-01
The purpose of this trial is to determine whether iodide supplementation of neonates born
under 31 weeks gestation improves neurodevelopment measured at two years of age.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
